Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)

Inclusion Criteria:

• Diagnosis of HS for at least 6 months prior to screening visit.

• Mild to moderate HS (Hurley I or II) with the following at both screening andbaseline visits:

• A total AN count of at least 4, with no draining tunnels AND

• Affecting at least 2 distinct anatomical areas

• Agreement to NOT use topical and systemic antibiotics for treatment of HS during thevehicle-controlled period.

• Agreement to NOT use topical antiseptics, including washes and leave-on products onthe areas affected by HS lesions during the vehicle-controlled period and Weeks 16to 20 of the extension period.

• Further inclusion criteria apply.

Exclusion Criteria:

• Body surface areas to be treated exceed 20% BSA at screening or baseline

• Presence of draining tunnels at screening or baseline.

• Medical history including current or history of certain infections, cancer,lymphoproliferative disorders and other medical conditions at the discretion of theinvestigator.

• Laboratory values outside of the protocol-defined criteria.

• Pregnant or lactating participants, or those considering pregnancy during the periodof their study participation.

• Further exclusion criteria apply.